Clinical trials: Panuveitis
Behcet Disease
Phase III Study in Refractory Behcet's Disease
The purpose of this pivotal trial is to evaluate subcutaneous (SQ) AIN457 as an adjunctive therapy to reduce the rate of exacerbations of posterior uveitis or panuveitis secondary to Behçet's disease during the 24 weeks of study…
- Trial name
- SHIELD (NCT00995709)
- Testing
- AIN457
- Where
- 49 sites in United States, Egypt and 15 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis, Ankylosing Spondylitis
Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
TRANSREG will assess the safety and biological efficacy of low-dose IL2 as a Treg inducer in a set of 14 autoimmune and auto-inflammatory diseases, with the aim to select diseases in which further therapeutic development will be…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus, Psoriasis
- Trial name
- TRANSREG (NCT01988506)
- Testing
- Interleukin 2
- Where
- 11 sites in France
- Volunteers
- 81 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Uveitis
Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
The purpose of the extension study was to provide patients completing the 28-week core study (NCT01095250) with an opportunity to receive an additional 22 weeks of continuous treatment.
- Trial name
- INSURE (NCT01103024)
- Testing
- AIN457
- Where
- 11 sites in United States, Canada and 3 more
- Sponsor
- Novartis
Uveitis, Anterior, Adalimumab
The Efficacy and Safety of Adalimumab in Non-infectious Anterior Pediatric Uveitis With Peripheral Vascular Leakage
Children with anterior uveitis are prone to suffer from chronic recurrent course of intraocular inflammation and adverse effects of glucocorticosteroids (GCs) /immunomodulatory treatment (IMT) agents.
- Trial name
- NCT05015335
- Testing
- Adalimumab, Methotrexate
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking Union Medical College Hospital
Metabolic Syndrome, Behcet Disease
Efficacy of Physical Activity Program in Metabolic-syndrome Females With Behcet Disease
metabolci syndrom is highly prevalent in behcet disorder females. usually physical activity is recommended to solve this problem
- Trial name
- NCT07702123
- Testing
- treadmill walking
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Behcet Syndrome
Tocilizumab for the Treatment of Behcet's Syndrome
This is a double-blind placebo controlled study targeting individuals with active Behcet's Syndrome who have oral ulcers and are resistant (have not responded after 4 weeks) to conventional treatments.
- Trial name
- NCT01693653
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- NYU Langone Health
Behçet Disease
A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease
This is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group study with an equal randomization among the Hemay005 high dose, lower dose and placebo treatment groups.
- Trial name
- NCT04609397
- Testing
- Hemay005
- Where
- 31 sites in China
- Volunteers
- 89 people
- Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
Anterior Uveitis
A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of non-infectious anterior uveitis.
- Trial name
- NCT00333996
- Testing
- Dexamethasone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Allergan
Anterior Uveitis, Uveitis
Topical Interferon Gamma for Macular Edema Secondary to Uveitis
The objective of this study is to investigate the safety and efficacy of ocular instillations of interferon gamma-1b as a potential treatment for cystoid macular edema (CME) secondary to uveitis.
- Trial name
- JakStat2 (NCT01376362)
- Testing
- Interferon Gamma-1b
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Eye Institute (NEI)
Behcet Disease
Asprosin in Behect Patients
This study aims to investigate serum Asprosin concentrations in patients with BD and their relationship with disease activity and major clinical manifestations.
- Trial name
- NCT07803198
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Assiut University
Aneurysm, Behcet Syndrome, Vascular Type
Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome
This project aims to evaluate the efficacy and safety of the combination of glucocorticoids with tocilizumab or tofacitinib, compared to the traditional combination of glucocorticoids with cyclophosphamide in the treatment of…
- Trial name
- NCT05845723
- Testing
- tocilizumab, tofacitinib, cyclophosphamide
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Peking Union Medical College Hospital
Behçet Disease
Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease
The aim of this study is to estimate the efficacy of apremilast compared to placebo in the treatment of oral ulcers in pediatric participants from 2 to < 18 years of age with oral ulcers associated with Behçet's disease (BD)…
- Trial name
- BEAN (NCT04528082)
- Testing
- Apremilast
- Where
- 27 sites in France, Greece and 6 more
- Volunteers
- 60 people
- Sponsor
- Amgen
Behçet's Disease, Psychiatric Disorders
Psychiatric Manifestations Associated With Behcet's Disease
The psychoBehçet'study is aimed at evaluating the psychological and neurocognitive symptoms in 25 consecutive patients followed for Behçet's disease. This is a monocentric, observational, non interventional study.
- Trial name
- PSYCHO-B7 (NCT04585360)
- Testing
- Questionnaires evaluating anxiety and depression symptoms, tiredness, and quality of life
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Behcet Disease and Vascular Affection
Serum Elafin and Vascular Affection in Behcet Disease
To measure the level of serum elafin in patients with BD. To assess the relation between serum elafin levels and disease activity.
- Trial name
- NCT06272929
- Testing
- doppler ultrasound
- Volunteers
- 90 people
- Sponsor
- Assiut University
Uveitis, Uveitis, Posterior
Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis
This open-label study is designed to evaluate the safety of suprachoroidally administered triamcinolone acetone injectable suspension, CLS-TA, in patients with non-infectious uveitis with and without macular edema.
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate
- Trial name
- AZALEA (NCT03097315)
- Testing
- 4 mg CLS-TA Suprachoriodal Injection
- Where
- 10 sites in United States
- Volunteers
- 38 people
- Sponsor
- Clearside Biomedical, Inc.
Systemic Lupus Erythematosus, Inflammatory Myopathy
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
The objective of this study is to evaluate the efficacy and safety of BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells in the treatment of autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus, Inflammatory Myopathy, Systemic Sclerosis (SSc), ANCA-associated Vasculitis
- Trial name
- NCT06794008
- Testing
- BCMA-CD19 CAR-T therapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Macular Edema, Cystoid, Uveitis
Vascular Endothelial Growth Factor (VEGF) in Uveitis
This study will look for the presence in blood of a substance called vascular endothelial growth factor (VEGF) in patients with uveitis (eye inflammation).
- Trial name
- NCT00001738
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Uveitis, Anterior
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis
The purpose of this study is to define a safe and effective dose of iontophoretic delivery of dexamethasone phosphate ophthalmic solution using the EyeGate® II Drug Delivery System in patients with non-infectious anterior segment…
- Trial name
- NCT00694135
- Testing
- EGP-437 1.6 mA-min at 0.4 with EyeGate® II System, EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System, EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System
- Where
- 19 sites in United States, India
- Volunteers
- 40 people
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Behcet's Syndrome, Intestinal Type, Myelodysplastic Syndrome
Ustekinumab for Intestinal Behçet's Syndrome With Myelodysplastic Syndrome
Behçet's syndrome is a systemic vasculitis. Gastrointestinal involvement in Behçet's syndrome complicated by myelodysplastic syndrome represents a rare and severe subtype for which no standardized treatment guidelines currently…
- Trial name
- NCT07582991
- Testing
- Ustekinumab 90 mg
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Liu Tian
Uveitis
38 Week Extension Study to CAIN457C2303
A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet's patients with posterior or panuveitis treated with…
- Trial name
- SHIELD (NCT01093846)
- Testing
- AIN457
- Where
- 25 sites in United States, Egypt and 12 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals